Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone for hypersexual disorder: open-label pilot feasibility study
2018-001049-15Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2018
- Countries
- 1
- Sponsor
- Anova Evidence
- Modality
- Small Molecules
- Drugs
- naltrexone
- Conditions
- hypersexuality
01
Overview
Phase 2, open-label, single-arm trial of naltrexone in hypersexuality, sponsored by Anova Evidence. Primary endpoint: Feasibility (primary). Started Jun 2018; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Naltrexone monotherapy
All enrolled participants receive open-label naltrexone for treatment of hypersexual disorder.
03
Who it enrols
Adults with a diagnosis of hypersexual disorder; patients with liver enzymes (ALAT or ASAT) greater than three times the upper limit of normal are excluded.
04
Endpoints
Primary
Feasibility (primary)
Secondary
Efficacy (exploratory)
Tolerability (exploratory)
Beyond the preview
Go deeper on 2018-001049-15.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001049-15.